Medpace Hldgs Analyst Ratings
Medpace Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 17.48% | Baird | $270 → $289 | Upgrades | Neutral → Outperform |
| 07/25/2023 | 10.98% | Guggenheim | $252 → $273 | Maintains | Buy |
| 05/08/2023 | 2.44% | Guggenheim | → $252 | Upgrades | Neutral → Buy |
| 02/15/2023 | -5.28% | Baird | $226 → $233 | Maintains | Neutral |
| 10/27/2022 | — | UBS | Upgrades | Sell → Neutral | |
| 10/26/2022 | -11.79% | Baird | $200 → $217 | Maintains | Neutral |
| 09/07/2022 | -42.28% | UBS | → $142 | Initiates Coverage On | → Sell |
| 05/24/2022 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 07/20/2021 | -16.67% | Credit Suisse | $200 → $205 | Maintains | Outperform |
| 03/17/2021 | -26.42% | Credit Suisse | $178 → $181 | Maintains | Outperform |
| 02/17/2021 | -26.83% | Truist Securities | $135 → $180 | Maintains | Buy |
| 02/16/2021 | -27.64% | Credit Suisse | $155 → $178 | Maintains | Outperform |
| 10/02/2020 | -45.12% | Truist Securities | $124 → $135 | Upgrades | Hold → Buy |
| 07/28/2020 | -53.66% | Credit Suisse | $92 → $114 | Maintains | Outperform |
| 06/08/2020 | -66.26% | Baird | → $83 | Upgrades | Underperform → Neutral |
| 04/30/2020 | -65.45% | SunTrust Robinson Humphrey | $54 → $85 | Upgrades | Sell → Hold |
| 04/29/2020 | -62.6% | Credit Suisse | $105 → $92 | Maintains | Outperform |
| 04/20/2020 | -68.7% | Baird | → $77 | Downgrades | Neutral → Underperform |
| 04/06/2020 | -78.05% | SunTrust Robinson Humphrey | $46 → $54 | Maintains | Sell |
| 03/23/2020 | -69.51% | Jefferies | $93 → $75 | Maintains | Hold |
| 03/17/2020 | -81.3% | SunTrust Robinson Humphrey | $100 → $46 | Downgrades | Hold → Sell |
| 02/25/2020 | -59.76% | Credit Suisse | $91 → $99 | Maintains | Outperform |
| 01/27/2020 | -64.63% | SunTrust Robinson Humphrey | $85 → $87 | Downgrades | Buy → Hold |
| 04/30/2019 | -74.8% | Baird | $57 → $62 | Maintains | Neutral |
| 10/31/2018 | — | SunTrust Robinson Humphrey | Upgrades | Hold → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月24日 | 17.48% | 貝爾德 | $270→$289 | 升級 | 中性→表現優異 |
| 07/25/2023 | 10.98% | 古根海姆 | $252→$273 | 維護 | 買 |
| 05/08/2023 | 2.44% | 古根海姆 | →$252 | 升級 | 中性→購買 |
| 02/15/2023 | -5.28% | 貝爾德 | $226→$233 | 維護 | 中性 |
| 10/27/2022 | - | 瑞銀集團 | 升級 | 賣出→中性 | |
| 10/26/2022 | -11.79% | 貝爾德 | $200→$217 | 維護 | 中性 |
| 09/07/2022 | -42.28% | 瑞銀集團 | →$142 | 開始承保 | →銷售 |
| 2022年05月24日 | - | 古根海姆 | 開始承保 | →中性 | |
| 07/20/2021 | -16.67% | 瑞士信貸 | $200→$205 | 維護 | 跑贏大盤 |
| 03/17/2021 | -26.42% | 瑞士信貸 | $178→$181 | 維護 | 跑贏大盤 |
| 02/17/2021 | -26.83% | Truist證券 | $135→$180 | 維護 | 買 |
| 02/16/2021 | -27.64% | 瑞士信貸 | $155→$178 | 維護 | 跑贏大盤 |
| 10/02/2020 | -45.12% | Truist證券 | $124→$135 | 升級 | 持有→購買 |
| 07/28/2020 | -53.66% | 瑞士信貸 | $92→$114 | 維護 | 跑贏大盤 |
| 06/08/2020 | -66.26% | 貝爾德 | →$83 | 升級 | 表現不佳的→中性 |
| 04/30/2020 | -65.45% | SunTrust Robinson Humphrey | $54→$85 | 升級 | 銷售→Hold |
| 04/29/2020 | -62.6% | 瑞士信貸 | $105→$92 | 維護 | 跑贏大盤 |
| 04/20/2020 | -68.7% | 貝爾德 | →$77 | 評級下調 | 中性→表現不佳 |
| 04/06/2020 | -78.05% | SunTrust Robinson Humphrey | $46→$54 | 維護 | 賣 |
| 03/23/2020 | -69.51% | 傑富瑞 | $93→$75 | 維護 | 保持 |
| 03/17/2020 | -81.3% | SunTrust Robinson Humphrey | $100→$46 | 評級下調 | 持有→Sell |
| 02/25/2020 | -59.76% | 瑞士信貸 | $91→$99 | 維護 | 跑贏大盤 |
| 2020/01/27 | -64.63% | SunTrust Robinson Humphrey | $85→$87 | 評級下調 | 購買→Hold |
| 2019年04月30日 | -74.8% | 貝爾德 | $57→$62 | 維護 | 中性 |
| 2018年10月31日 | - | SunTrust Robinson Humphrey | 升級 | 持有→購買 |
What is the target price for Medpace Hldgs (MEDP)?
Medace Hldgs(MEDP)的目標價格是多少？
The latest price target for Medpace Hldgs (NASDAQ: MEDP) was reported by Baird on October 24, 2023. The analyst firm set a price target for $289.00 expecting MEDP to rise to within 12 months (a possible 17.48% upside). 6 analyst firms have reported ratings in the last year.
貝爾德公司於2023年10月24日報道了Medace Hldgs(納斯達克代碼：MEDP)的最新目標價。這家分析公司將目標價定為289.00美元，預計MEDP將在12個月內上漲(可能上漲17.48%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Medpace Hldgs (MEDP)?
Medace Hldgs(MEDP)的最新分析師評級是多少？
The latest analyst rating for Medpace Hldgs (NASDAQ: MEDP) was provided by Baird, and Medpace Hldgs upgraded their outperform rating.
貝爾德對Medace Hldgs(納斯達克代碼：MEDP)的最新分析師評級是由Baird提供的，Medace Hldgs上調了其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Medpace Hldgs (MEDP)?
Medace Hldgs(MEDP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medpace Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medpace Hldgs was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Medace Hldgs的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Medace Hldgs的上一次評級是在2023年10月24日提交的，所以你應該預計下一次評級將在2024年10月24日左右的某個時候提供。
Is the Analyst Rating Medpace Hldgs (MEDP) correct?
分析師對Medace Hldgs(MEDP)的評級正確嗎？
While ratings are subjective and will change, the latest Medpace Hldgs (MEDP) rating was a upgraded with a price target of $270.00 to $289.00. The current price Medpace Hldgs (MEDP) is trading at is $246.00, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Medace Hldgs評級被上調，目標價為270.00美元至289.00美元。目前Medace Hldgs的交易價格為246.00美元，超出了分析師的預期區間。